CAR T-cell and Bispecific Therapies: Clinical Applications and Nursing Management

Click Here to Participate

Recorded on: April 26, 2024
1.5 CE Credit/Contact hours for nurses and social workers available until: December 11, 2025
1.5 CE Contact hours for nurse practitioners available until: June 30, 2025
ILNA Accredited
Format: Non-interactive recorded webinar 

 

Target Audience

This CE activity is intended for oncology nurses, nurse practitioners, and social workers involved in the care of patients with hematologic malignancies. 

Course content level for social workers: all levels

Description

Expand your knowledge on the availability and application of CAR T-cell and bispecific therapies to treat patients with hematologic malignancies. Follow a patient from diagnosis, through therapy, and follow-up monitoring while providing input on the patient’s care! Learn about the newest treatments, safety and efficacy, patient management, barriers to access/care, resources for patient education and support from The Leukemia & Lymphoma Society, and more, all to improve patient care! 

Learning Objectives

Upon completion, participants should be better able to:

• Describe the role of CAR T- cell therapy and bispecifics in treating blood cancer
• Apply knowledge of communication strategies, streamlined patient assessment, disparities in care, and strategies for multidisciplinary teams to improve patient-centered care
• Explain data surrounding CAR T-cell and bispecific therapies including their proper application, efficacy, and adverse events, and resources to support patients and their caregivers
• Optimize patient assessment to ensure effective, individualized patient care including implementation of bridging therapy when indicated 
• Utilize appropriate tools to properly assess risk for progression and response to cellular therapies

Faculty

Jessica R. Kassay-McAllister, DNP, RN, AGACNP-BC 
Oncology APP Manager
Division of Hematology/Oncology
Cellular Therapy/Stem Cell Transplant Program, Effector Cell NP
UVA School of Nursing Clinical Faculty
University of Virginia Comprehensive Cancer Center
Charlottesville, VA

Krithika Shanmugasundaram, MD
Assistant Professor of Medicine, Division of Hematology/Oncology
University of Virginia Comprehensive Cancer Center
Charlottesville, VA

Dan T. Vogl, MD, MSCE
Director, Abramson Cancer Center Clinical Research Unit
Associate Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Continuing Education Information

For Nurses
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing. 

Social Worker Continuing Education
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credit.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed -social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hour for this activity.
 

Nurse Practitioner Continuing Education

This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.35 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24066677. This activity was planned in accordance with AANP Accreditation Standards and Policies.

ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care of the Pediatric Hematology and Oncology Patient (CPHON), Cellular Collection, Preparative Regimens, and Infusion (BMTCN), Early Post-Transplant Management and Education (BMTCN), Foundations of Transplant (BMTCN), Late Post-Transplant Management and Education (BMTCN), Oncologic Emergencies (OCN, CPHON, AOCNP), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Quality of Life (BMTCN), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Transplant Process and Infusion (BMTCN), Treatment (OCN, CBCN, AOCNP, CPHON). 
Total points: 1.5*
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Providers

This activity is provided by The Leukemia & Lymphoma Society.  

Supporters

This activity is supported in part by an educational grant from Bristol Myers Squibb. Additional funding provided by The Leukemia & Lymphoma Society.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.